China's drug clinical trial volume has surpassed 5,000, marking a new historical high according to the National Medical Products Administration's 2025 report. This includes nearly 3,000 new drug clinical trials and over 2,200 bioequivalence trials. Separately, South Korea's Financial Supervisory Service is considering measures for leveraged ETFs due to sustained retail investor demand for high-risk products, and is investigating a SpaceX IPO allocation failure by Mirae Asset. AI
RANK_REASON The cluster contains multiple unrelated news items, one about Chinese drug trials and another about South Korean financial regulation, lacking a single cohesive event.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
